Therapeutic and subtherapeutic doses of pregabalin were compared to ascertain differences in adherence, healthcare resource use, and cost between the cohorts.
Robert J. Sanchez, PhD
Advertisement
Articles by Robert J. Sanchez, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
3
Beyond Weight Loss: Exploring the Renal and Anti-Inflammatory Benefits of High-Dose Semaglutide
4
ADA 2026: The 2026 ADA Standards – A Pharmacist's Guide to Cardiorenal Risk Reduction
5